Cargando…

Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis

This study investigated the inhibitory effect of levocarnitine supplementation on sarcopenia progression in hepatocellular carcinoma (HCC) patients treated with lenvatinib. We evaluated the skeletal muscle index (SMI). After propensity score matching for age, sex, modified albumin-bilirubin grade, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Hironao, Ando, Hitoshi, Nakadera, Eisuke, Ikejima, Kenichi, Shiina, Shuichiro, Nagahara, Akihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705344/ https://www.ncbi.nlm.nih.gov/pubmed/34959980 http://dx.doi.org/10.3390/nu13124428

Ejemplares similares

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
por: Okubo, Hironao, et al.
Publicado: (2022)

Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma
por: Okubo, Hironao, et al.
Publicado: (2020)

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment
por: Okubo, Hironao, et al.
Publicado: (2022)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Gadoxetic acid–enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C
por: Okubo, Hironao, et al.
Publicado: (2018)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

Endobronchial Watanabe Spigot Placement for Hepatic Abscess and Bronchobiliary Fistula Following Radiofrequency Ablation for Hepatocellular Carcinoma
por: Nishioki, Toshihiko, et al.
Publicado: (2022)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
por: Jing, Zheng, et al.
Publicado: (2023)

Significance of Levocarnitine Treatment in Dialysis Patients
por: Takashima, Hiroyuki, et al.
Publicado: (2021)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
por: Graziano, F, et al.
Publicado: (2002)

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis
por: Dong, Dong, et al.
Publicado: (2022)

Effects of Levocarnitine Treatment on the Cardiac Function in Hemodialysis Patients
por: Maruyama, Takashi, et al.
Publicado: (2018)

Effect of levocarnitine administration in patients with chronic liver disease
por: Ohashi, Kazuki, et al.
Publicado: (2020)

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
por: Toshida, Katsuya, et al.
Publicado: (2022)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis
por: Chewcharat, Api, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
por: Higuchi, Terumi, et al.
Publicado: (2014)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

High-Flux Hemodialysis and Levocarnitine in the Treatment of Severe Valproic Acid Intoxication
por: Temel, V., et al.
Publicado: (2013)

MON-065 Prevention of 6-Mercaptopurine-Induced Hypoglycemia by Levocarnitine Replacement
por: Torchinsky, Michael Yuri, et al.
Publicado: (2020)

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis
por: Chen, Yu-Xing, et al.
Publicado: (2022)

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
por: Shimose, Shigeo, et al.
Publicado: (2023)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Benefit of an action camera in endoscopy education for medical students under COVID-19
por: Uchiyama, Akira, et al.
Publicado: (2023)

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
por: Choi, Na Ryung, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
por: Guo, Peng, et al.
Publicado: (2022)

Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review
por: Brown, Lauren M., et al.
Publicado: (2018)

Levocarnitine for pegaspargase‐induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia
por: Schulte, Rachael, et al.
Publicado: (2021)

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy
por: Abe, Kazumichi, et al.
Publicado: (2021)

A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders
por: Geier, David A., et al.
Publicado: (2011)

Topical Delivery of Levocarnitine to the Cornea and Anterior Eye by Thermosensitive in-situ Gel for Dry Eye Disease
por: Ma, Baorui, et al.
Publicado: (2021)

Levocarnitine regulates the growth of angiotensin II-induced myocardial fibrosis cells via TIMP-1
por: Shu, Jin, et al.
Publicado: (2023)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ugda01056j7stje92mcah4i2uo